Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 4 (2007), Issue 2 (February)

1. Prospective Study of Positron Emission Tomography for Evaluation of the Activity of Lapatinib, a Dual Inhibitor of the ErbB1 and ErbB2 Tyrosine Kinases, in Patients with Advanced Tumors.
   Jpn J Clin Oncol, 37(1): 44-8. [Abstract] [Full-text]
2. Influence of oil droplet surface charge on the performance of antibody-emulsion conjugates.
   Biomed Pharmacother, 61(1): 97-103. [Abstract] [Full-text]
3. Locally advanced breast cancer in a 15th century painting in Milan.
   Breast, 16(1): 102-3. [Abstract] [Full-text]
4. Progress and new standards of care in the management of HER-2 positive breast cancer.
   Eur J Cancer, 43(3): 497-509. [Abstract] [Full-text]
5. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
   Eur J Cancer, 43(3): 481-9. [Abstract] [Full-text]
6. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
   Cancer Res, 67(3): 1170-5. [Abstract] [Full-text]
7. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice.
   Cancer Res, 67(3): 1138-44. [Abstract] [Full-text]
8. Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer.
   Genes Chromosomes Cancer, 46(4): 397-405. [Abstract] [Full-text]
9. Chromogenic in-situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
   J Clin Pathol. [Abstract] [Full-text]
10. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
    Breast Cancer Res, 9(1): R17. [Abstract] [Full-text]
11. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
    Int J Pharm, 331(2): 190-6. [Abstract] [Full-text]
12. Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
    J Med Chem, 50(4): 603-6. [Abstract] [Full-text]
13. Managing high-risk breast cancer.
    Semin Oncol Nurs, 23(1): 29-36. [Abstract] [Full-text]
14. Serum HER2 levels are increased in patients with chronic heart failure.
    Eur J Heart Fail, 9(2): 173-177. [Abstract] [Full-text]
15. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    J Clin Oncol, 25(6): 634-41. [Abstract] [Full-text]
16. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    J Clin Oncol, 25(6): 625-33. [Abstract] [Full-text]
17. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Cancer Res, 67(4): 1487-93. [Abstract] [Full-text]
18. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.
    Cancer Res, 67(4): 1436-41. [Abstract] [Full-text]
19. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Mol Cancer Ther, 6(2): 667-74. [Abstract] [Full-text]
20. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
    Clin Cancer Res, 13(4): 1238-45. [Abstract] [Full-text]
21. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
    Clin Cancer Res, 13(4): 1198-207. [Abstract] [Full-text]
22. Why we will need to learn new skills to control cancer.
    Intern Med J, 37(3): 201-4. [Abstract] [Full-text]
23. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
    Eur J Cancer, 43(4): 725-35. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.